Latest news with #AkebiaTherapeutics
Yahoo
4 days ago
- Business
- Yahoo
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating
Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy rating and a $8 price target, on June 4. The analyst gave the optimistic rating due to the company's VAFSEO product and its potential in the CKD anemia market. VAFSEO is an approved treatment for anemia in adults with chronic kidney disease on dialysis. According to the analyst, the treatment is gaining considerable momentum among dialysis organizations, and this trend is anticipated to support near-term growth. He expects VAFSEO's ongoing launch to offset the effect of generics on AURYXIA, another product by Akebia Therapeutics, Inc. (NASDAQ:AKBA) that deals with hyperphosphatemia. A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics. The analyst also reasoned that Akebia Therapeutics, Inc. (NASDAQ:AKBA) is positioned for success as it has secured contracts that cover almost all dialysis patients in the US. VAFSEO offers flexibility in its dosing regimen, ranging from 150mg to 600mg, making it a factor that allows for personalized treatment and potentially growing prescriptions. Caufield pointed out VAFSEO's oral administration as another reason supporting the optimistic rating, giving it an advantage over existing therapies, such as iron supplementation and erythropoiesis-stimulating agents. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company that develops and commercializes drugs to treat metabolic and renal diseases. While we acknowledge the potential of AKBA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
13-05-2025
- Business
- Yahoo
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, and Nik Grund, Chief Commercial Officer, will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20 at 2:30 PM EDT. A webcast of the presentation can be accessed through the 'Investors' section of Akebia's website at following the conference. The H.C. Wainwright BioConnect Investor Conference will take place on May 20, 2025, at the Nasdaq Headquarters in New York City. About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at which does not form a part of this release. Akebia Therapeutics ContactMercedes Carrascomcarrasco@
Yahoo
10-05-2025
- Business
- Yahoo
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates
Akebia Therapeutics (AKBA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 200%. A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.08 per share when it actually produced a loss of $0.10, delivering a surprise of -25%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Akebia Therapeutics , which belongs to the Zacks Medical - Drugs industry, posted revenues of $57.34 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 26.83%. This compares to year-ago revenues of $32.61 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Akebia Therapeutics shares have added about 29.5% since the beginning of the year versus the S&P 500's decline of -4.3%. While Akebia Therapeutics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Akebia Therapeutics: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.04 on $44.05 million in revenues for the coming quarter and -$0.12 on $192.75 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, NewAmsterdam Pharma Company N.V. (NAMS), is yet to report results for the quarter ended March 2025. This company is expected to post quarterly loss of $0.45 per share in its upcoming report, which represents a year-over-year change of +27.4%. The consensus EPS estimate for the quarter has been revised 0.6% lower over the last 30 days to the current level. NewAmsterdam Pharma Company N.V.'s revenues are expected to be $2.77 million, up 97.6% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Akebia Therapeutics, Inc. (AKBA) : Free Stock Analysis Report NewAmsterdam Pharma Company N.V. (NAMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-05-2025
- Business
- Yahoo
Akebia Therapeutics First Quarter 2025 Earnings: Beats Expectations
Revenue: US$57.3m (up 76% from 1Q 2024). Net income: US$6.11m (up from US$18.0m loss in 1Q 2024). Profit margin: 11% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. EPS: US$0.026 (up from US$0.088 loss in 1Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 29%. Earnings per share (EPS) also surpassed analyst estimates. Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are up 4.1% from a week ago. Before you take the next step you should know about the 3 warning signs for Akebia Therapeutics (1 is a bit concerning!) that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
